CytoDyn Cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV
June 09, 2015 06:30 ET
|
CytoDyn
VANCOUVER, Wash., June 9, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Submits Phase 3 Protocol to FDA After Agreement on Protocol Synopsis
May 04, 2015 16:01 ET
|
CytoDyn
Six Months of Monotherapy With PRO 140 Has Been Effective for HIV Patients in Phase 2b Study
Conference Call Scheduled for May 5 at 1:00 p.m. PT / 4:00 p.m. ET
VANCOUVER, Wash., May 4,...
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy - Many HIV Patients in Extension Study With Some Approaching 6 Months
February 03, 2015 08:45 ET
|
CytoDyn
VANCOUVER, Wash., Feb. 3, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program
November 24, 2014 08:00 ET
|
CytoDyn
VANCOUVER, Wash., Nov. 24, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial
October 13, 2014 08:00 ET
|
CytoDyn
VANCOUVER, Washington, Oct. 13, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...
CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIV
October 10, 2014 16:26 ET
|
CytoDyn
VANCOUVER, Wash., Oct. 10, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
CytoDyn Appoints Carl Dockery to Board of Directors
October 01, 2014 15:43 ET
|
CytoDyn
VANCOUVER, Wash., Oct. 1, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
CytoDyn Announces Webcast for Annual Shareholder Meeting
August 15, 2014 15:06 ET
|
CytoDyn
VANCOUVER, Wash., Aug. 15, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
July 31, 2014 08:20 ET
|
CytoDyn
VANCOUVER, Wash., July 31, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...
CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
July 30, 2014 21:51 ET
|
CytoDyn
VANCOUVER, Wash., July 30, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...